Here are the latest stories being discussed in biopharma today:

1. ‘GSK Sues Pfizer and BioNTech Over Alleged mRNA Patent Infringement’
GlaxoSmithKline (GSK) has filed a lawsuit against Pfizer and BioNTech, arguing that the two companies utilized GSK’s patented mRNA research in their development of a Covid-19 vaccine. Pfizer has rejected these charges.

2. ‘Sage Therapeutics Enhances Focus on Launch of Postpartum Depression Drug’
Sage Therapeutics is amping up its promotional efforts for Zurzuvae, their groundbreaking postpartum depression drug. Aiming to tap into its ‘blockbuster potential,’ they already have a consumer website operational and more outreach initiatives underway.

3. ‘Spanish Company Esteve to Purchase Perrigo’s Rare Disease Pharma Business for $295 Million’
Barcelona-based pharmaceutical Esteve Healthcare is set to acquire Perrigo’s rare disease drug assets. The deal, worth up to $295 million, is expected to close in the third quarter.

4. ‘FDA Proposes Revised Guidance on Biosimilar Labels and Advertising’
The FDA has proposed updates to their guidance on biologics and biosimilars’ labeling and advertising. This move follows their recent request to Congress to drop the interchangeability designation for biosimilars.

5. ‘Colombia Issues Compulsory License for HIV Medicine, First Time Ever’
The Colombian government issued a compulsory license for dolutegravir, a commonly used HIV drug. This marks the first-ever government authorization to manufacture a medication without the original maker’s consent, potentially reducing costs for patients significantly.

6. ‘Merck KGaA to Invest €300M+ in New Research Center at German Headquarters’
Merck KGaA is allocating over €300 million for the construction of a new research building at their Darmstadt, Germany headquarters. The new Advanced Research Center, expected to house 550 workers by 2027, will focus on studies for the company’s life science business.

7. ‘Walgreens to Expand Specialty Pharmacy Business, Concentrating on Drug and Therapy Services’
(Story omitted from source info)

8. ‘Despite Setbacks in Oncology, Sanofi Still in the Race with Early Assets’
(Story omitted from source info)

9. ‘Bristol Myers Announces $1.5B in Cost Cuts And Job Eliminations in Company Reorganization’
(Story omitted from source info)

10. ‘Roche Undeterred by China Bill As It Continues to Establish Its Presence in the Region’
(Story omitted from source info)